Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




New Immunoassay Bead Expands IVD Offering

By HospiMedica staff writers
Posted on 06 Dec 2006
A new immunoassay bead has been developed for in vitro diagnostic (IVD) applications. More...
The immunoassay provides highly precise immobilization of small antigens such as peptides, steroids, and hormones to the surface of the beads.

The beads include a controlled number of carboxylic acid groups. The antigen of choice can then be coupled to the beads, either directly or via a linker, using carbodiimide- mediated amide bond formation. This reduces the need for bovine serum albumin (BSA) blocking, which is often used to avoid non-specific binding of serum proteins that would otherwise interfere with the assay.

The superparamagnetic beads, called Dynabeads, exhibit magnetic properties when placed within a magnetic field and show no residual magnetism when removed from this field. Dynabeads are a product of Dynal, a company that now belongs to Invitrogen (Grand Island, NY, USA). The true spherical shape and defined surface chemistry of the beads minimize chemical agglutination and non-specific binding. The specific characteristics of the many available bead types facilitate magnetic separation of a wide variety of targets. Separation is gentle and no column or centrifugations are necessary.

The new Dynabeads MyOne immunoassay provides an excellent solid support for antigen-down immunoassays. The hydrophilic surface ensures low non-specific binding, excellent dispersion abilities, and easy handling in a wide variety of buffers. The beads also have a high magnetic mobility in combination with a low sedimentation rate, making them ideal for automated assays. Furthermore, Dynabeads do not inhibit enzymatic activity and can be included directly in downstream analysis of the bead-bound target molecule. Alternatively, the target molecule can be eluted off the Dynabeads using conventional elution methods.

Hege Skjellerudsveen, Dynal IVD product manager said, "The new low charge carboxyl immunoassay bead, expands our excellent IVD bead offering. It is particularly suited to infectious disease testing, along with other antibody tests (autoimmune, allergy, small molecule hormones, and drugs). It gives customers the opportunity to develop antigen-based assays more easily, as well as with much higher consistency and sensitivity compared to alternative techniques.”



Related Links:
Invitrogen

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
Gold Member
UGPIV Barrier and Securement
UltraDrape II
Blood Bank Refrigerator
MBR-705GR-PE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.